| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Maestracci, D Grimaud, N Livrelli, F Philip, C Dolis. Increase in hepatic blood flow and cardiac output during dopamine infusion in man. Critical care medicine. vol 9. issue 1. 1981-04-24. PMID:7460572. |
dopamine, therefore, increased both ehbf and co, but the existence of intrahepatic dopaminergic receptors could not be established. |
1981-04-24 |
2023-08-12 |
human |
| C Y Cheung, R W Kuhn, R I Weine. Increased responsiveness of the dopamine-mediated inhibition of prolactin synthesis after destruction of the medial basal hypothalamus. Endocrinology. vol 108. issue 3. 1981-04-24. PMID:7460839. |
long term destruction of the tuberoinfundibular dopaminergic neurons results in increased responsiveness of the anterior pituitary to the suppression of prl release by dopamine. |
1981-04-24 |
2023-08-12 |
rat |
| J J Braszko, M J Bannon, B S Bunney, R H Rot. Intrastriatal kainic acid: acute effects on electrophysiological and biochemical measures of nigrostriatal dopaminergic activity. The Journal of pharmacology and experimental therapeutics. vol 216. issue 2. 1981-04-21. PMID:6257886. |
the results are discussed in terms of the role of strionigral pathways in mediating the acute effects of kainic acid on the nigrostriatal dopaminergic system and are interpreted in light of the recently described phenomenon of presumed dopamine cell depolarization inactivation. |
1981-04-21 |
2023-08-12 |
Not clear |
| A Cheramy, V Leviel, J Glowinsk. Dendritic release of dopamine in the substantia nigra. Nature. vol 289. issue 5798. 1981-04-13. PMID:6258083. |
dopamine can be released in the substantia nigra for the dendrites of nigrostriatal dopaminergic neurones, to be involved there in the self-regulation of the dopaminergic cells, to control the release of neurotransmitters from nigral afferent fibres and to influence the activity of nigral non-dopaminergic cells. |
1981-04-13 |
2023-08-12 |
Not clear |
| O Hornykiewic. [Brain dopamine and brain disorders - and what we have learned from these studies (author's transl)]. Wiener klinische Wochenschrift. vol 92. issue 20. 1981-04-13. PMID:7467350. |
this observation, taken together with the fact that all antipsychotically effective neuroleptics are potent blockers of brain dopamine receptors, has lead to the hypothesis that dopaminergic brain mechanisms are involved in the pathophysiology of the schizophrenic disorder(s). |
1981-04-13 |
2023-08-12 |
Not clear |
| B R Cooper, T J Hester, R A Maxwel. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. The Journal of pharmacology and experimental therapeutics. vol 215. issue 1. 1981-03-27. PMID:6778989. |
results indicate that bupropion is a selective dopamine uptake inhibitor in vivo and that dopaminergic systems play an important role in its central nervous system pharmacology. |
1981-03-27 |
2023-08-12 |
rat |
| A J Daniels, K Gysling, L Arquero. Intraneuronal site of action for imipramine in rat striatal slices. Journal of neurochemistry. vol 35. issue 3. 1981-03-27. PMID:7452282. |
it is proposed that imipramine enters the dopaminergic storage vesicles and displaces dopamine. |
1981-03-27 |
2023-08-12 |
rat |
| R Jackisch, A Zumstein, G Hertting, K Stark. Interneurones are probably not involved in the presynaptic dopaminergic control of dopamine release in rabbit caudate nucleus. Naunyn-Schmiedeberg's archives of pharmacology. vol 314. issue 2. 1981-03-27. PMID:7453832. |
interneurones are probably not involved in the presynaptic dopaminergic control of dopamine release in rabbit caudate nucleus. |
1981-03-27 |
2023-08-12 |
rabbit |
| R Jackisch, A Zumstein, G Hertting, K Stark. Interneurones are probably not involved in the presynaptic dopaminergic control of dopamine release in rabbit caudate nucleus. Naunyn-Schmiedeberg's archives of pharmacology. vol 314. issue 2. 1981-03-27. PMID:7453832. |
it is concluded that the presynaptic dopaminergic modulation of dopamine release is not mediated by a tetrodotoxin-sensitive interneuronal pathway. |
1981-03-27 |
2023-08-12 |
rabbit |
| S H Shi. Physiological evidence for the existence of prolactin releasing factor: stress-induced prolactin secretion is not linked to dopaminergic receptors. Neuroendocrinology. vol 31. issue 6. 1981-03-17. PMID:6779219. |
since the putative pif is dopamine, complete blockage of the dopaminergic pif receptors should permit demonstration of prf activity. |
1981-03-17 |
2023-08-12 |
rat |
| K T Demarest, D J Smith, A J Azzar. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. The Journal of pharmacology and experimental therapeutics. vol 215. issue 2. 1981-02-26. PMID:7441510. |
the nigrostriatal dopaminergic pathway was selected as a model system to determine the form (i.e., type a or b) of monoamine oxidase (mao) present within central dopamine (da)-containing neurons. |
1981-02-26 |
2023-08-12 |
rat |
| I S Hoffmann, R J Naylor, L X Cubedd. Presynaptic effects of 2-aminotetralins on striatal dopaminergic neurons. The Journal of pharmacology and experimental therapeutics. vol 215. issue 2. 1981-02-26. PMID:7441511. |
the present study evaluated whether 2-amino-5,6-dihydroxy-1,2,3,4,-tetrahydronaphthalene (a-5,6 dtn) and its 6,7-dihydroxy isomer (a-6,7 dtn) had effects on striatal dopaminergic terminals in addition to their well known action as agonists on postsynaptic dopamine (da)-receptors. |
1981-02-26 |
2023-08-12 |
rat |
| D P Goodale, D B Rusterholz, J P Long, J R Flynn, B Walsh, J G Cannon, T Le. Neurochemical and behavioral evidence for a selective presynaptic dopamine receptor agonist. Science (New York, N.Y.). vol 210. issue 4474. 1981-02-24. PMID:7444443. |
a new dopamine analog, 6,7-dihydroxy-2-dimethylaminotetralin (tl-99), was compared to apomorphine in three tests of dopaminergic function in the central nervous system. |
1981-02-24 |
2023-08-12 |
rat |
| P M Beart, A L Gundlac. 3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms. British journal of pharmacology. vol 69. issue 2. 1981-02-19. PMID:6108139. |
1 drug effects on dopamine catabolism of the mesolimbic dopaminergic pathway have been investigated using a sensitive radioenzymatic assay for 3,4-dihydroxyphenylacetic acid (dopac). |
1981-02-19 |
2023-08-12 |
rat |
| P M Beart, A L Gundlac. 3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms. British journal of pharmacology. vol 69. issue 2. 1981-02-19. PMID:6108139. |
6 similarities exist between the dopamine catabolism in somatodendritic and nerve terminal regions of mesolimbic dopaminergic neurones in the response to neuroleptic drugs, but differences in catabolism are evident following certain pharmacological treatments such as reserpine and gamma-butyrolactone. |
1981-02-19 |
2023-08-12 |
rat |
| P M Beart, A L Gundlac. 3,4-dihydroxyphenylacetic acid (DOPAC) and the rat mesolimbic dopaminergic pathway: drug effects and evidence for somatodendritic mechanisms. British journal of pharmacology. vol 69. issue 2. 1981-02-19. PMID:6108139. |
7 dopamine release occurs in the somatodendritic region of mesolimbic dopaminergic neurones and release sites may be dendritic as has been found for nigrostriatal dopaminergic neurones. |
1981-02-19 |
2023-08-12 |
rat |
| E G Bradshaw, B J Pleuvry, H L Sharm. Effect of droperidol on dopamine-induced increase in effective renal plasma flow in dogs. British journal of anaesthesia. vol 52. issue 9. 1981-02-19. PMID:7437226. |
small doses of dopamine are known to produce renal vasodilatation by a dopaminergic mechanism and droperidol, a selective dopamine antagonist used in neuroleptanaesthesia, may attenuate this response. |
1981-02-19 |
2023-08-12 |
Not clear |
| L Annunziato, P Leblanc, C Kordon, R I Weine. Differences in the kinetics of dopamine uptake in synaptosome preparations of the median eminence relative to other dopaminergically inervated brain regions. Neuroendocrinology. vol 31. issue 5. 1981-02-19. PMID:7442934. |
uptake in the median eminence appeared to be predominantly into dopaminergic terminals since preincubation with desipramine did not affect the maximum velocity (vmax) of dopamine uptake. |
1981-02-19 |
2023-08-12 |
Not clear |
| M Munemura, T E Cote, K Tsuruta, R L Eskay, J W Kebabia. The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization. Endocrinology. vol 107. issue 6. 1981-01-29. PMID:6107242. |
the dopamine receptor in the intermediate lobe (il) of the hypophysis of the rat is characterized on the basis of the ability of dopamine and other dopaminergic agonists to decrease the consequences of activation of the beta-adrenoceptor. |
1981-01-29 |
2023-08-12 |
rat |
| M Munemura, T E Cote, K Tsuruta, R L Eskay, J W Kebabia. The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization. Endocrinology. vol 107. issue 6. 1981-01-29. PMID:6107242. |
the dopamine receptor in the il can be assigned to the category of dopamine receptor designated d-2 on the basis of the following criteria: 1) occupancy of the dopamine receptor does not result in enhancement of adenylate cyclase activity or an accumulation of camp, 2) the dopaminergic ergots and apomorphine mimic the inhibitory effect of dopamine upon camp formation or alpha msh release, and 3) metoclopramide and sulpiride, substituted benzamides, block the inhibitory effect of dopamine. |
1981-01-29 |
2023-08-12 |
rat |